Why you're not losing weight on Mounjaro in the first week

What SURMOUNT-1 tells us about timing (and what it doesn't)

The landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, ran for 72 weeks. Over 2,500 adults took part. Average weight loss at the highest tirzepatide dose reached approximately 20–21% of starting body weight, but that figure accumulated across the full course of treatment. If you are wondering whether you lose weight in the first week on Mounjaro, the trial offers a useful answer: it did not report week-one losses precisely, because week one is not where tirzepatide works.

The first pen delivers 2.5 mg per week. That dose is not therapeutic in the way the 10 or 15 mg maintenance doses are. Its job is tolerability: giving your gut hormone receptors time to adapt before the dose climbs. NICE's appraisal of tirzepatide, published as TA1026, recognises that the full benefit of the medicine plays out over the longer titration period. Expecting a visible change at week one sets a benchmark the drug was never designed to meet.

For a broader sense of what the first days on treatment actually feel like (appetite shifts, energy changes, the odd queasy morning) the first week on Mounjaro page covers the practical reality.

Three reasons the scales stay flat (that have nothing to do with the medicine failing)

Even when fat tissue does start to reduce, the number on the scale can stay stubbornly still. Here is why.

Water and glycogen shifts. Reducing calorie intake (which most people do almost automatically once tirzepatide quietens appetite) causes the body to draw on glycogen stores. Glycogen holds water. As stores deplete, the body can also retain water temporarily through different mechanisms, so early weight readings are noisy. A 0.5 kg swing between morning and evening is entirely normal regardless of treatment.

Digestive slowdown. Tirzepatide slows gastric emptying, that is part of how it works. Your gut is holding food for longer. More food in the digestive tract at any moment means slightly more mass when you weigh yourself. This is transient and unrelated to fat stores.

The 2.5 mg plateau. The appetite suppression that drives meaningful eating reduction tends to become more pronounced at higher doses. Many people on 2.5 mg report mild changes to hunger but nothing like the effect they notice at 5 mg or 7.5 mg. That is not failure; it is the medicine doing exactly what the dose is designed to do. If you want to understand more about the wider picture of slow or stalled progress, not losing weight on Mounjaro explores what to do when the plateau persists longer-term.

What you might notice before the number moves

A question our prescribers hear regularly: "I feel different, but the scale is the same, is something happening?" Almost always, yes.

Appetite is usually the first signal. Finishing a meal earlier than usual, losing interest in snacking that felt automatic before, finding that food simply occupies less mental space, these are signs the medicine is engaging with the GIP and GLP-1 receptors it targets. Reduced calorie intake follows, and that does eventually show on the scale, but the lag between eating less and the scale catching up is real and sometimes frustrating.

Tracking non-scale signals during the first weeks (energy, portion sizes, cravings) gives a more honest picture of what is actually happening than daily weigh-ins. Weighing once a week, same time, same conditions, gives more useful data than daily readings that reflect hydration and digestion as much as anything else.

For a fuller explanation of the typical timeline from first injection to measurable results, how long Mounjaro takes to work covers the titration arc in detail.

When to talk to a prescriber rather than wait

First-week non-response is normal. Sustained non-response (no meaningful progress after several months at the highest tolerated dose) is worth a clinical conversation. NICE's TA1026 guidance notes that continuing treatment should be reviewed if weight loss falls below 5% after six months at the maximum tolerated dose. That is a long-run benchmark, not a week-one one.

If you are experiencing side effects that are making it hard to stick to your dose schedule, or if something about your response to the medicine feels unexpected, that is a different matter and should go to your prescriber promptly. The NHS tirzepatide medicines page lists common side effects and explains which require urgent attention.

At nume, a real clinician (a GPhC-registered Independent Prescriber, not a decision tree) reads every consultation the same day. Your treatment is assessed individually; if something needs adjusting, that is what aftercare support is for. Your pen arrives in a plain, unbranded box via DPD with a tracking link on your phone, and the aftercare team is available seven days a week if questions come up between doses. Prescriptions are not renewed automatically, a clinical review precedes each repeat, which is also the right moment to flag any concerns about progress.

On cost, tirzepatide is a private prescription medicine, and Mounjaro's cost in the UK varies by dose and provider. If you are at the stage of exploring whether treatment is right for you, checking eligibility is the sensible first step. Check your eligibility with a free consultation, there is no obligation and no automated decision.